Pharmacological Targeting of Mitochondria in Diabetic Kidney Disease
Pharmacological Reviews · 2023-03 · 75 (2) · 250-262
DOI: 10.1124/pharmrev.122.000560 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Reviews, 2023-03. Verfasst von Kristan H Cleveland und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology and Toxicology, University of Arizona, Tucson, Arizona (K.H.C., R.G.S.) and Southern VA Healthcare System, Tucson, Arizona (R.G.S.). Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperglycemia. Die Arbeit wurde bisher 139-mal zitiert (Crossref) und nennt 132 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Pharmacology and Toxicology, University of Arizona, Tucson, Arizona (K.H.C., R.G.S.) and Southern VA Healthcare System, Tucson, Arizona (R.G.S.).
- Pharmacology and Toxicology, University of Arizona, Tucson, Arizona (K.H.C., R.G.S.) and Southern VA Healthcare System, Tucson, Arizona (R.G.S.) schnell@arizona.edu.
Zitieren
APA
Cleveland, K. H., & Schnellmann, R. G. (2023). Pharmacological Targeting of Mitochondria in Diabetic Kidney Disease. Pharmacological Reviews, 75(2), 250-262. https://doi.org/10.1124/pharmrev.122.000560
Vancouver
Cleveland KH, Schnellmann RG. Pharmacological Targeting of Mitochondria in Diabetic Kidney Disease. Pharmacological Reviews. 2023;75(2):250-262. doi:10.1124/pharmrev.122.000560
BibTeX
@article{Cleveland2023,
author = {Cleveland, Kristan H and Schnellmann, Rick G},
title = {Pharmacological Targeting of Mitochondria in Diabetic Kidney Disease},
journal = {Pharmacological Reviews},
year = {2023},
volume = {75},
number = {2},
pages = {250--262},
doi = {10.1124/pharmrev.122.000560}
}
EUVIMED